These authors contributed equally to this work.
Liver Injury and Regeneration
Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model
Article first published online: 24 JUL 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 3, pages 1133–1142, September 2013
How to Cite
Seki, A., Sakai, Y., Komura, T., Nasti, A., Yoshida, K., Higashimoto, M., Honda, M., Usui, S., Takamura, M., Takamura, T., Ochiya, T., Furuichi, K., Wada, T. and Kaneko, S. (2013), Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model. Hepatology, 58: 1133–1142. doi: 10.1002/hep.26470
Potential conflict of interest: Nothing to report.
Supported in part by subsidies from the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Japanese Ministry of Health, Labor and Welfare.
- Issue published online: 29 AUG 2013
- Article first published online: 24 JUL 2013
- Accepted manuscript online: 17 MAY 2013 08:40AM EST
- Manuscript Accepted: 15 APR 2013
- Manuscript Received: 27 SEP 2012
Cirrhosis is a chronic liver disease that impairs hepatic function and causes advanced fibrosis. Mesenchymal stem cells have gained recent popularity as a regenerative therapy since they possess immunomodulatory functions. We found that injected adipose tissue-derived stem cells (ADSCs) reside in the liver. Injection of ADSCs also restores albumin expression in hepatic parenchymal cells and ameliorates fibrosis in a nonalcoholic steatohepatitis model of cirrhosis in mice. Gene expression analysis of the liver identifies up- and down-regulation of genes, indicating regeneration/repair and anti-inflammatory processes following ADSC injection. ADSC treatment also decreases the number of intrahepatic infiltrating CD11b+ and Gr-1+ cells and reduces the ratio of CD8+/CD4+ cells in hepatic inflammatory cells. This is consistent with down-regulation of genes in hepatic inflammatory cells related to antigen presentation and helper T-cell activation. Conclusion: These results suggest that ADSC therapy is beneficial in cirrhosis, as it can repair and restore the function of the impaired liver. (Hepatology 2013;53:1133–1142)